Teva Appoints Dr. R. Ananthanarayanan as CEO for Teva API, Strengthening its Active Pharmaceutical Ingredients Business

Teva Pharmaceutical Industries Ltd. has recently announced the appointment of Dr. R. Ananthanarayanan (Ananth) as the CEO of its Teva Active Pharmaceutical Ingredients business (Teva API). This strategic move aims to support Teva's plan of transforming Teva API into a standalone business and further solidify its position as a leading player in the pharmaceutical industry.

Dr. Ananth brings with him over 34 years of experience in leading global API businesses, both in sales and internal operations. With a deep understanding of Teva's API business from his previous role as the head of Teva API and Biologics Operations, Dr. Ananth is poised to lead the transformation of Teva API and drive growth in this critical aspect of Teva's Pivot to Growth strategy.

Teva's President and CEO, Richard Francis, expressed his excitement in welcoming Dr. Ananth to the team, stating that his extensive knowledge of the industry landscape and Teva's business will be invaluable in maximizing revenue streams, enhancing customer service, and ultimately delivering better outcomes for patients.

Dr. Ananth's previous roles include Chief Executive Officer positions at a leading Contract Development and Manufacturing Organization (CDMO) for large-scale production of Active Ingredients, as well as at Strides Pharma Science Limited, a global generic pharmaceutical company. He also served as the Chief Operating Officer at Cipla Limited. Throughout his career, Dr. Ananth has held various leadership positions in operations, business development, and P&L in the global pharmaceutical industry, further highlighting his expertise in the field.

Expressing his enthusiasm for returning to Teva, Dr. Ananth stated that he is confident in Teva's strategic vision and believes in the company's potential to create a more focused end-to-end operation that will make a significant impact and value for Teva and the patients they serve worldwide.

Teva Pharmaceutical Industries Ltd. has been at the forefront of developing and producing medicines for over a century. As a global leader in both generic and innovative medicines, Teva's extensive portfolio consists of over 3,500 products catering to various therapeutic areas. With a significant presence in generics and continuous research and development efforts, Teva remains committed to improving the lives of millions around the world.

It's worth noting that this press release contains forward-looking statements, subject to various risks and uncertainties. These statements are based on management's current beliefs and expectations, and actual results may differ significantly. Factors that may contribute to such differences include, but are not limited to, the successful execution of Teva's Pivot to Growth strategy, attracting and retaining skilled personnel, compliance with regulatory environments, economic risks, and other factors discussed in Teva's financial reports.

In conclusion, Teva's appointment of Dr. R. Ananthanarayanan as the CEO for Teva API marks a significant milestone in the company's journey toward a more focused and successful active pharmaceutical ingredients business. With Dr. Ananth's expertise and Teva's commitment to innovation and patient care, the future looks promising for Teva and its stakeholders.